Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intuitive Surgical reports robust Q4 performance and eyes future growth

Intuitive Surgical's Q4 2022 showcased strong performance and growth in procedures and system placements.
While facing challenges like macroeconomic uncertainty and supply chain costs, the company is poised for continued innovation.
Opportunities lie in expanding markets, advancing technology, and improving surgical outcomes through collaboration.
Investments in industrial scale, automation, and platform advancements signal a strategic focus on future growth.

Intuitive Surgical (ISRG) reports robust Q1 performance and growth outlook

Intuitive Surgical (ISRG) delivered strong Q1 results with revenue up 14% and exceeding procedure growth expectations.
While facing challenges in manufacturing and supply chain, the company is focusing on R&D progress and inventory replenishment.
The outlook for 2023 looks promising with increased procedure growth forecasts and a focus on improving patient outcomes and market expansion.
Overall, Intuitive Surgical (ISRG) is well-positioned to capitalize on opportunities for growth and innovation in the robotic surgery market.

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Vertex Pharmaceuticals

Healthcare spending represents a tremendous, multitrillion-dollar market opportunity. Vertex just earned another product approval, and more growth could be just over the horizon.

2 Healthcare Stocks That Could Help Set You Up for Life

Airbnb

Upstart Holdings

Intuitive Surgical relies on a proven model to drive its dominance of robotic surgery. Airbnb is recording unprecedented growth figures, helped by its asset-light approach.

3 Revolutionary Stocks I'd Buy Right Now Without Hesitation

Clearpoint Neuro Inc

Healthcare stocks are one of the best sectors to capture long-term innovation and sector strength. After all, healthcare needs are perennial, especially as the global population lives longer and can generally afford more than the bare minimum of care.

3 Strong Buy Healthcare Stocks to Add to Your February Must-Watch List

CRISPR Therapeutics

CRISPR Therapeutics' recent regulatory approval should be the first of others to come. Intuitive Surgical has a long runway despite recent headwinds from weight-loss medicines.

2 Healthcare Stocks to Buy Hand Over Fist in February

GlaxoSmithKline

Johnson & Johnson

Medtronic

Pfizer

Teladoc

Healthcare stocks in 2024 are charting an impressive course, emerging as formidable contenders in the investment sphere. After weathering a challenging 2023, these stocks are on the rise, with the S&P 500 Health Care index showcasing an almost 11% rise in the last three months alone.

The 7 Best Healthcare Stocks to Invest In for Big Gains in 2024

Nucor

Two investors share their big winners, and whether they plan to keep holding.

Finding Winners: My Best-Performing Stock and It Isn't Even Close

Intuitive Surgical ISRG (NASDAQ NDAQ : ISRG) reported its Q4 results last month, with revenues and earnings beating the street estimates. The company reported revenue of $1.93 billion, up 17% y-o-y and above the $1.89 billion consensus estimate.

Should You Pick Intuitive Surgical Stock At $375 After An Upbeat Q4?

ABB Ltd

iRobot

The advancements in AI and the rapid progress in automation have led to this list of robotics stocks in 2024 for investors to consider. This transformation is not just limited to manufacturing and industrial sectors but has expanded into healthcare and even consumer goods and services.

The 3 Best Robotics Stocks to Invest In for Big Gains in 2024

UiPath

Zebra Technologies

As the human world hurtles into a future shaped by cutting-edge technologies, the robotics sector stands at the forefront of transformative growth. The article delves into the promising trajectories of three robotics stocks, each with the potential for a staggering 250% growth by 2025.

3 Robotics Stocks With 250% Growth Potential by 2025

Abbott Labs

Stryker

Med tech stocks have been a mixed bag of results the last two years, with most moving within established trading ranges. The impact of COVID and its effect on procedure volumes were slow to dissipate, and the growth outlook was uncertain, leaving the market for their stock without a solid catalyst to drive it despite many trading at value levels and paying healthy dividends.

4 med tech stocks with improving prognosis for 2024

Intuitive Surgical is the most recent addition to the publicly shared Moats and Monopolies Portfolio. It has first mover advantage in a large and expanding global opportunity. Its robotic assisting surgical devices improve patient outcomes and procedures using them are increasing.

Intuitive Surgical: Buy A 'Little Slice' Of The Future

Intuitive Surgical (ISRG) aims to boost its da Vinci portfolio with the addition of its next-generation da Vinci 5 multiport surgical robot.

Intuitive Surgical (ISRG) Seeks FDA Nod for Next-Gen da Vinci 5

Intuitive Surgical's (ISRG) fourth-quarter results reflect healthy demand for procedures, partially offset by lower system sales. Higher pricing boosts procedure sales.

Intuitive Surgical (ISRG) Q4 Earnings Beat, Procedures Robust

Intuitive Surgical NASDAQ: ISRG share prices surged following the Q4 release but failed to hold the gain, creating an ugly candle capping a strong rally. The market may move lower from here, but if so, it will present an even better entry point into this medtech pioneer than is already apparent.

Intuitive Surgical's post-earnings dip is a healthy time to buy

Intuitive Surgical Inc. (ISRG), the maker of the da Vinci surgical robot, posted better-than-expected fourth-quarter results, with demand for non-invasive operations increasing.

Intuitive Surgical Beats Forecasts as Procedures with Its Da Vinci Robot Rose

Improving procedure volumes and solid recurring revenue are key catalysts.

Medical Instrument Provider Eyes Breakout Amid Upbeat Earnings Results

Intuitive submits an application to the Food and Drug Administration for its new surgical robot, the Da Vinci 5.

Intuitive Surgical Stock Pops. There Could Be a New Surgery Robot on the Way.

Intuitive Surgical increasingly incorporates AI into the hardware and software tools that power its robotic systems. Upstart uses AI to drive better lending decisions, and a more favorable lending environment could turn its balance sheet around.

These 2 Magnificent Growth Stocks Are Worth Buying in 2024 and Holding Long Term

The headline numbers for Intuitive Surgical, Inc. (ISRG) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Here's What Key Metrics Tell Us About Intuitive Surgical, Inc. (ISRG) Q4 Earnings

Intuitive Surgical, Inc. (ISRG) Q4 2023 Earnings Call Transcript

Regeneron Pharmaceuticals

Blue-chip healthcare stocks tend to be among the top portfolio picks for long-term investors today. Though their blue-chip status implies maturity, which they have, it also implies that the companies have limited growth prospects.

3 Blue-Chip Healthcare Stocks to Buy and Hold Forever: January 2024

Intuitive Surgical beat earnings views Tuesday, helped by strong procedure growth for its robotic surgery system. But ISRG stock rallied.

Robotic Surgery Giant Intuitive Surgical Rallies With A Profit-Taking Zone In View

Intuitive Surgical beat Wall Street estimates for fourth-quarter revenue and profit on Tuesday, as a recovery in surgeries lifted demand for its robots used in minimally invasive procedures.

Intuitive beats estimates as rebound in surgeries boost demand for its robots

SUNNYVALE, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended December 31, 2023.

Intuitive Announces Fourth Quarter Earnings

Intuitive Surgical's (ISRG) fourth-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs might have hurt margins.

News for Intuitive Surgical Stock (ISRG)